Author: Robert Iansek Publisher: Cambridge University Press ISBN: 110701400X Category : Medical Languages : en Pages : 263
Book Description
Provides a broad overview of current rehabilitation approaches, emphasizing the need for interdisciplinary management and focussing on deliverable outcomes.
Author: J. Eric Ahlskog, PhD, MD Publisher: Oxford University Press ISBN: 0190231882 Category : Health & Fitness Languages : en Pages : 545
Book Description
The fundamental guide to the most effective treatments for Parkinson's Disease, from a Mayo Clinic doctor with thirty years of clinical and research experience. In this second edition follow-up to the extremely successful first edition, Dr. Ahlskog draws on thirty years of clinical experience to present the definitive guide to dealing with all aspects of Parkinson's Disease, from treatment options and side effects to the impact of the disease on caregivers and family. Dr. Ahlskog's goal is to educate patients so that they can better team up with their doctors to do battle with the disease, streamlining the decision-making process and enhancing their treatment. To do this, Dr. Ahlskog offers a gold mine of information, distilled from his years of experience treating people with Parkinson's at the Mayo Clinic. In addition to providing a comprehensive account of Parkinson's medications, this book also examines additional aspects of treatment, such as the role of nutrition, exercise, and physical therapy. Although many commendable texts have been written on the subject of Parkinson's Disease, their discussions of treatment have not been in depth. Dr. Ahlskog sifts through aspects of the disease in order to give the reader a comprehensive sense of Parkinson's and the best available treatment options. With a broader understanding of the disease and the available options, patients are able to make more informed choices, and doctors are able to provide more tailored care. This book delivers hopeful, helpful, and extensive information to all parties concerned: patients, caregivers, and doctors. The ultimate guide to symptoms and treatment, this thoroughly updated second edition is the first place patients should turn for reliable, easy-to-grasp information on Parkinson's Disease.
Author: Sridhar P. Arjunan Publisher: Springer Nature ISBN: 9811630569 Category : Technology & Engineering Languages : en Pages : 173
Book Description
This book describes the range of technologies that have been developed for diagnosing and assessing Parkinson’s disease patients. Also presenting the latest studies providing insights into the changes to the neural system in Parkinson’s disease, it is a valuable resource for neurologists, general practitioners and nurses. Further, the book highlights areas that require more research, and as such will appeal to researchers, biomedical engineers and clinicians.
Author: Marilyn Trail Publisher: SLACK Incorporated ISBN: 9781556427718 Category : Medical Languages : en Pages : 384
Book Description
'Neurorehabilitation in Parkinson's Disease' serves as a reference for the treatment of patients with Parkinson's disease. In addition to providing treatment models for physical therapy, occupational therapy, & speech-language pathology, the text covers topics such as review of pathophysiology, & symptomatology.
Author: Martina Mancini Publisher: Academic Press ISBN: 0128138750 Category : Medical Languages : en Pages : 228
Book Description
Balance Dysfunction in Parkinson's Disease: Basic Mechanisms to Clinical Management presents the most updated information on a variety of topics. Sections help clinicians evaluate the types of balance control issues, dynamic balance dysfunction during turning, and the effects of medication, deep brain stimulation, and rehabilitation intervention on balance control. This book is the first to review the four main postural control systems and how they are affected, including balance during quiet stance, reactive postural adjustments to external perturbations, anticipatory postural adjustments in preparation for voluntary movements, and dynamic balance control during walking and turning. In addition, the book's authors summarize the effects of levodopa, deep brain stimulation, and rehabilitation intervention for each balance domain. This book is recommended for anyone interested in how and why balance control is affected by PD. - Provides the first comprehensive review of research to date on balance dysfunctions in Parkinson's disease - Discusses how to translate current neuroscience research into practice regarding neural control of balance - Provides evidence on the effects of current interventions on balance control
Author: Maria Nord Publisher: Linköping University Electronic Press ISBN: 9176855570 Category : Languages : sv Pages : 81
Book Description
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Author: Edward Bezkor Publisher: F.A. Davis ISBN: 1719647739 Category : Medical Languages : en Pages : 1268
Book Description
Achieve the best functional outcomes for your patients. Here is a practical, step-by-step guide to understanding the treatment process and selecting the most appropriate interventions for your patients. Superbly illustrated, in-depth coverage shows you how to identify functional deficits, determine what treatments are appropriate, and then implement them to achieve the best functional outcome for your patients. Learn through reading, seeing, and doing. Seventeen case studies in the text correspond to seventeen videotaped case studies with voice-over narration online at FADavis.com. These videos show you how practicing therapists interact with their clients in rehabilitation settings…from sample elements of the initial examination through the interventions to the functional outcomes…to make a difference in patients’ lives.
Author: Management Association, Information Resources Publisher: IGI Global ISBN: 1799834425 Category : Medical Languages : en Pages : 671
Book Description
Cognitive impairment, through Alzheimer’s disease or other related forms of dementia, is a serious concern for afflicted individuals and their caregivers. Understanding patients’ mental states and combatting social stigmas are important considerations in caring for cognitively impaired individuals. Technology is playing an increasing role in the lives of the elderly. One of the most prevalent developments for the aging population is the use of technological innovations for intervention and treatment of individuals with mental impairments. Research Anthology on Diagnosing and Treating Neurocognitive Disorders examines the treatment, diagnosis, prevention, and therapeutic and technological interventions of neurodegenerative disorders. It also describes programs and strategies that professional and family caregivers can implement to engage and improve the quality of life of persons suffering from cognitive impairment. Highlighting a range of topics such as dementia, subjective wellbeing, and cognitive decline, this publication is an ideal reference source for speech pathologists, social workers, occupational therapists, psychologists, psychiatrists, neurologists, pediatricians, researchers, clinicians, and academicians seeking coverage on neurocognitive disorder identification and strategies for clinician support and therapies.
Author: Robert Iansek
Author: J. Eric Ahlskog, PhD, MD
Author: Mario Bernardo-Filho
Author: Sridhar P. Arjunan
Author: Marilyn Trail
Author: Nicola Smania
Author: Martina Mancini
Author: Maria Nord
Author: Edward Bezkor
Author: Management Association, Information Resources